Table 2. Laboratory findings for study participants.
| Total (n = 60) | Chloroquine (n = 20) | Controls (n = 40) | P-value | |
|---|---|---|---|---|
| Onset of symptoms to blood test (days); median (IQR) | 13 (10–15) | 14 (10–15) | 12 (10–14) | 0.231 |
| Troponin T, ng/L; median (IQR) | 14.4 (8.0–47.3) | 10.8 (7.4–22.8) | 17.9 (8.0–55.1) | 0.111 |
| NT-proBNP, ng/L; median (IQR) | 349 (132–1000) | 399 (143–1235) | 349 (130–765) | 0.784 |
| eGFR, mL/min/1.73m2 | 77a (59–71) | 76 (67–86) | 78b (58–92) | 0.848 |
| Creatinine, μmol/L; median (IQR) | 78a (71–102) | 86 (74–94) | 77b (71–105) | 0.749 |
| Potassium, mmol/L; median (IQR) | 4.0a (3.7–4.3) | 4.2 (3.9–4.4) | 4.0b (3.7–4.2) | 0.365 |
| CRP, mg/L; median (IQR) | 135c (73–260) | 180 (63–300) | 125d (79–188) | 0.399 |
| White blood cell count, 109/L; median (IQR) | 7.8 (5.8–10.1) | 7.5 (5.8–9.5) | 8.3 (6.0–10.3) | 0.351 |
| B-lymphocytes, 109/L; median (IQR) | 1.0 (0.8–1.3) | 1.1 (0.9–1.3) | 1.0 (0.8–1.2) | 0.162 |
| Neutrophils, 109/L; median (IQR) | 6.4 (4.5–8.7) | 5.5 (4.2–7.9) | 6.8 (4.7–8.8) | 0.154 |
| Thrombocytes, 109/L; median (IQR) | 240e (166–363) | 271 (216–385) | 230f (162–347) | 0.152 |
IQR = interquartile range, eGFR = estimated glomerular filtration rate, CRP = C-reactive protein, NT-proBNP = N-terminal prohormone of brain natriuretic peptide.
a Data available for 59 patients.
b Data available for 39 patients.
c Data available for 58 patients.
d Data available for 38 patients.
e Data available for 54 patients.
f Data available for 34 patients.